Brind.

Addex Therapeutics led a CHF 2 million investment in Stalicla and appointed its CEO to the board.

2 reports, 0 independent Updated Jun 30

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Addex Therapeutics led a CHF 2 million investment in Stalicla and appointed its CEO to the board.

Who's involved

What this event is mainly about

Addex Therapeutics

Keep exploring

The entities involved

Addex Therapeutics
Swiss public company
- Indivior and Addex Therapeutics regained full global rights to GABAB PAM assets.Mon 06:10
- Addex Therapeutics and Indivior are partnering on a drug candidate.Fri 07:58

Related events

Addex Therapeutics and Bayer Aktiengesellschaft are being compared as healthcare companies.Wed 21:19
Addex Therapeutics and Enanta Pharmaceuticals are being analyzed as competing small-cap healthcare companies.Sep 9

Coverage

Newest first; wire copies grouped

Jun 30Unknown outlet
Jun 25Unknown outlet